TWI734331B - 鳳梨萃取物的護膚用途 - Google Patents
鳳梨萃取物的護膚用途 Download PDFInfo
- Publication number
- TWI734331B TWI734331B TW108148714A TW108148714A TWI734331B TW I734331 B TWI734331 B TW I734331B TW 108148714 A TW108148714 A TW 108148714A TW 108148714 A TW108148714 A TW 108148714A TW I734331 B TWI734331 B TW I734331B
- Authority
- TW
- Taiwan
- Prior art keywords
- skin
- cells
- pineapple
- pineapple peel
- peel extract
- Prior art date
Links
- 235000007119 Ananas comosus Nutrition 0.000 title claims description 76
- 239000000284 extract Substances 0.000 title description 59
- 244000099147 Ananas comosus Species 0.000 title 1
- 229940013712 pineapple extract Drugs 0.000 claims abstract description 20
- 239000011148 porous material Substances 0.000 claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 16
- 230000002708 enhancing effect Effects 0.000 claims abstract description 12
- 241000234671 Ananas Species 0.000 claims description 75
- 210000003491 skin Anatomy 0.000 claims description 63
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 26
- 102000005720 Glutathione transferase Human genes 0.000 claims description 25
- 108010070675 Glutathione transferase Proteins 0.000 claims description 25
- 229960003180 glutathione Drugs 0.000 claims description 23
- 239000003963 antioxidant agent Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 210000004927 skin cell Anatomy 0.000 claims description 11
- 108010024636 Glutathione Proteins 0.000 claims description 10
- 239000002932 luster Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 230000008099 melanin synthesis Effects 0.000 abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 230000001413 cellular effect Effects 0.000 abstract description 4
- 230000036571 hydration Effects 0.000 abstract 1
- 238000006703 hydration reaction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 84
- 239000000243 solution Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 239000006143 cell culture medium Substances 0.000 description 12
- 239000007758 minimum essential medium Substances 0.000 description 12
- 210000001626 skin fibroblast Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 10
- 230000036564 melanin content Effects 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000014128 RANK Ligand Human genes 0.000 description 3
- 108010025832 RANK Ligand Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- -1 troche Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001244920 Eucomis bicolor Species 0.000 description 1
- 238000010631 GST assay Methods 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
- A21D13/06—Products with modified nutritive value, e.g. with modified starch content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本發明提供一種鳳梨萃取物用於製備在皮膚抑制黑色素生成、增加含水量、提升光澤、及減少毛孔之醫藥組合物之用途,亦提供一種鳳梨萃取物用於製備提升細胞抗氧化力之醫藥組合物之用途。
Description
本發明係關於一種鳳梨萃取物的用途,特別係關於一種鳳梨果皮萃取物用於製備在皮膚抑制黑色素生成、增加含水量、提升光澤、及減少毛孔之醫藥組合物之用途,及一種鳳梨果皮萃取物用於製備提升細胞抗氧化力之醫藥組合物之用途。
皮膚是人體隔絕外界環境中的刺激,例如紫外線、病原體、摩擦力等,與防止水分流失的首要防線。皮膚具有表皮層、真皮層、及皮下組織之三層結構。表皮是皮膚的最外層並且不斷更新。表皮與真皮間存在持續分裂的細胞,例如纖維母細胞、角質細胞、黑色素細胞。真皮層富含膠原蛋白、彈性蛋白、及吸水力強的玻尿酸,其賦予肌膚彈性和支撐力量。由於年齡增長及環境刺激,皮膚會出現斑點、膚色黯沉、皺紋、鬆弛、凹陷、及毛孔粗大等老化外觀,並且累積氧化傷害。為了延緩皮膚老化,抑制黑色素過度生成、增加皮膚含水量及提升皮膚抗氧化力極為重要。
習知用以改善皮膚老化外觀的方法包括對皮膚施用抑制黑色素生成的化合物,及注射膠原蛋白或玻尿酸至真皮層。然而,部分抑制黑色素生成的化合物可能導致皮膚過敏,例如麴酸(kojic acid)。此外,注射至皮膚的膠原蛋白或玻尿酸易隨時間被體內酵素分解,導致必須定期施打該些物質,成本高昂。
此外,習知提升皮膚抗氧化力的方法主要是直接使用抗氧化劑於皮膚。該些抗氧化劑雖能協助清除造成皮膚細胞損傷的自由基,但無法透過改變細胞生理條件而提升皮膚細胞本身的抗氧化力。
有鑑於此,開發一種兼具皮膚美白、增加皮膚含水量、及提升細胞抗氧化力的組合物以製備新型態的護膚產品,實有其必要。
本發明之一目的在提供一種鳳梨萃取物用於製備在皮膚抑制黑色素生成、增加含水量、提升光澤、及減少毛孔之醫藥組合物之用途,其中該鳳梨萃取物係以一溶劑萃取一鳳梨果皮而獲得。
在本發明之一實施例中,該溶劑與該鳳梨果皮之重量比範圍為20:1至1:1,較佳為10:1至1:1。
在本發明之一實施例中,該溶劑為水,且該萃取係在50℃至100℃進行,較佳為65℃至85℃。
本發明之另一目的在提供一種前述鳳梨萃取物用於製備提升細胞抗氧化力之醫藥組合物之用途。
在本發明之一實施例中,該鳳梨萃取物增加該細胞內穀胱甘肽(glutathione,簡稱GSH)的含量,或增加該細胞之穀胱甘肽S轉移酶(glutathione S-transferase,簡稱GST)活性。
本發明揭露鳳梨萃取物具有抑制黑色素生成及改善膚質的功效,包括提升皮膚含水量與光澤及減少毛孔。該鳳梨萃取物亦能提升包含皮膚細胞之多種細胞的抗氧化力,藉此減少個體或皮膚的氧化傷害。因此,該鳳梨萃取物可用於製備在皮膚抑制黑色素生成、增加含水量、提升光澤、及減少毛孔之組合物,或製備提升細胞抗氧化力之組合物。該組合物可具有粉末、顆粒、溶液、膠體或膏體之形式,且可製成醫藥品、食品、飲品、或營養補充劑,藉由口服、局部施用於皮膚或其他方式給予一個體。
以下將配合圖式進一步說明本發明的實施方式,下述所列舉的實施例係用以闡明本發明之特點及應用,而非用以限定本發明之範圍,任何熟習此技藝者,在不脫離本發明之精神和範圍內,當可做些許更動與潤飾,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。
圖1顯示皮膚纖維母細胞以本發明一實施例之鳳梨果皮萃取物處理後的穀胱甘肽相對含量。
圖2顯示肝癌細胞株以本發明一實施例之鳳梨果皮萃取物處理後的穀胱甘肽相對含量。
圖3顯示皮膚纖維母細胞以本發明一實施例之鳳梨果皮萃取物處理後的穀胱甘肽S轉移酶活性。
圖4顯示外周血單核細胞以本發明一實施例之鳳梨果皮萃取物處理後的穀胱甘肽S轉移酶活性。
圖5顯示本發明一實施例之鳳梨果皮萃取物對過氧化氫(H2O2)刺激下皮膚纖維母細胞活性氧物質生成的抑制作用。
圖6顯示黑色素瘤細胞以本發明一實施例之鳳梨果皮萃取物處理後的黑色素相對含量。
圖7顯示受試者施用一含1%鳳梨果皮萃取物之面膜組合物或一基底精華液之前或施用15分鐘後的皮膚含水量。
圖8顯示受試者施用一含1%鳳梨果皮萃取物之面膜組合物或一基底精華液之前或施用15分鐘後的皮膚光澤度。
圖9顯示受試者施用一含1%鳳梨果皮萃取物之面膜組合物或一基底精華液之前或15分鐘後的皮膚毛孔數量。
除非另有說明,本文中所使用之「一」、「該」及類似用語應理解為包含單數及複數形式。
本文中所使用數值為近似值,所有實驗數據皆表示在20%的範圍內,較佳為在10%的範圍內,最佳為在5%的範圍內。
本文所述的醫藥組合物可利用熟習此技藝者所詳知的技術而製備成一適合於非經腸道地(parenterally)或口服地(orally)施用的劑型(dosage form),其包括但不限於:注射品(injection)[例如,無菌的水性溶液(sterile aqueous solution)或分散液(dispersion)]、粉末(sterile powder)、錠劑(tablet)、片劑(troche)、口含錠(lozenge)、丸劑(pill)、膠囊(capsule)、分散性粉末(dispersible powder)、細
顆粒(granule)、溶液、懸浮液(suspension)、乳劑(emulsion)、糖漿(syrup)、酏劑(elixir)、濃漿(slurry)以及類似之物。
本文所述的醫藥組合物可由非經腸道途徑(parenteral routes)施用,其包括但不限於:透皮(transdermal)施用、腹膜內注射(intraperitoneal injection)、皮下注射(subcutaneous injection)、肌肉內注射(intramuscular injection)、及靜脈內注射(intravenous injection)。
本文所述的醫藥組合物可包含一廣泛使用於藥物製造技術之醫藥上可接受的載劑(pharmaceutically acceptable carrier)。該醫藥上可接受的載劑可包含一或多種選自於由下列所構成之群組中的試劑:溶劑(solvent)、乳化劑(emulsifier)、懸浮劑(suspending agent)、分解劑(decomposer)、黏結劑(binding agent)、賦形劑(excipient)、安定劑(stabilizing agent)、螯合劑(chelating agent)、稀釋劑(diluent)、膠凝劑(gelling agent)、防腐劑(preservative)、潤滑劑(lubricant)、吸收延遲劑(absorption delaying agent)、脂質體(liposome)以及類似之物。該些試劑的選用與數量落在熟習此項技術者的專業素養與例行技術範疇內。
前述醫藥上可接受的載劑包含有一選自於由下列所構成之群組中的溶劑:水、生理鹽水(normal saline)、磷酸鹽緩衝鹽溶液(phosphate buffered saline,PBS)、含糖溶液、含醇水溶液(aqueous solution containing alcohol)、及它們的組合。
自Thermo Fisher Scientific公司購買含Earle’s平衡鹽溶液之Eagle’s最低基本培養基(Gibco Eagle’s minimum essential medium,MEM)、DMEM培養基(Gibco Dulbecco’s modified Eagle’s medium)、胎牛血清(Gibco fetal bovine serum,FBS)、青黴素/鏈黴素(Gibco penicillin/streptomycin)、非必需胺基酸、碳酸氫鈉、丙酮酸鈉、及磷酸緩衝鹽溶液(Gibco phosphate buffered saline,PBS)。自PEPROTECH公司購買人類巨噬細胞聚落刺激因子(macrophage colony stimulating factor,M-CSF)及人細胞核因子KB受體活化因子配體(receptor activator of nuclear factor kappaB ligand,RANKL)。自abcam公司購買穀胱甘肽檢測試劑組(GSH Assay Kit ab112132)及穀胱甘肽S轉移酶活性檢測試劑組(GST
Activity Assay Kit ab65326)。自ECHO Chemical公司購買二甲基亞碸(dimethyl sulfoxide,DMSO)。自Sigma公司購買過氧化氫(H2O2)及二氯二氫螢光素二乙酸酯(2,7-dichloro-dihydro-fluorescein diacetate,DCFH-DA)。該DCFH-DA使用前係溶於DMSO以配製為5mg/mL DCFH-DA溶液。
以下實施例所用細胞包括購自食品工業發展研究所生物資源保存及研究中心(Bioresource Collection and Research Center,BCRC)之人類皮膚纖維母細胞CCD-966SK(ATCC BCRC 60153),以及購自美國典型培養物保存中心(American Type Culture Collection,ATCC)之小鼠黑色素瘤細胞株B16F10(ATCC CRL-6475)、人類肝癌細胞株HepG2(ATCC HB-8065)、及人類外周血單核細胞(peripheral mononuclear mononuclear cell,PBMC)。CCD-966SK細胞在37℃、5%二氧化碳的條件下培養於添加10% FBS、1mM丙酮酸鈉、1.5g/L碳酸氫鈉、及0.1mM非必需胺基酸之MEM培養基,以下稱MEM細胞培養基。PBMC細胞在37℃、5%二氧化碳的條件下培養於添加10% FBS、40ng/mL RANKL、25ng/mLM-CSF、1%青黴素/鏈黴素的MEM培養基,以下稱蝕骨細胞分化培養基。B16F10細胞及HepG2細胞係在37℃、5%二氧化碳的條件下培養於添加10% FBS及1%青黴素/鏈黴素的DMEM培養基,以下稱DMEM細胞培養基。
細胞內GSH含量之測定係使用abcam之GSH檢測試劑組。簡言之,依據廠商使用說明,以PBS溶液清洗經過指定處理的細胞及再懸浮該細胞於1mL PBS溶液。其後,以巰基染劑(稀釋1000倍)在37℃對該細胞染色15分鐘。該染劑本是非螢光化合物,但與巰基反應後會發出綠色螢光。染色後,該細胞以PBS溶液清洗及再懸浮於200μL PBS溶液,再以流式細胞儀(flow cytometry;BD)偵測綠色螢光訊號(激發波長為490nm,偵測波長為520nm)。
細胞內GST活性之測定係使用abcam之GST活性檢測試劑組。簡言之,依據廠商使用說明,以PBS溶液清洗經過指定處理的細胞及再懸浮該細胞於150μL GST檢測緩衝液(GST assay buffer),藉由吸放(pipetting)該懸浮液數次以獲得一細胞裂解液。其後,以離心方式(10000g,4℃,15分鐘)收集該細胞裂解
液的上清液。將50μL/孔之該上清液(實驗組)、正控制組試劑、或GST檢測緩衝液加入一96孔盤,並於各孔添加5μL GSH及50μL反應液(含1μL GST受質溶液及49μL GST檢測緩衝液),所得混合液於室溫反應並且每隔3分鐘測量在340nm的吸光值(OD340),持續15分鐘。最終,計算每分鐘的OD340變化及進一步計算GST活性。
黑色素瘤細胞株B16F10的黑色素含量測定方法簡述如下。自經過指定處理的細胞培養物中收集細胞。該細胞以PBS溶液清洗並以胰蛋白酶(trypsin)溶液處理3分鐘,所得懸浮細胞以離心方式(400 xg,5分鐘)收集,經PBS溶液清洗二次,而後再懸浮於200μLPBS溶液。該細胞懸浮液以液態氮冷凍10分鐘,再置於室溫約30分鐘至完全解凍後,以離心方式(12,000 xg,3分鐘)移除上清液。餘下細胞沉澱與120μL之1N氫氧化鈉水溶液混合均勻,再於60℃加熱1小時以獲得一含溶解黑色素的細胞裂解液。將100μL該細胞裂解液移入一96孔盤,並使用ELISA讀盤機(enzyme-linked immunosorbent assay reader;BioTek)測量該細胞裂解液在450nm的吸光值(OD 450)。黑色素相對含量係依下列公式計算:
黑色素相對含量(%)=(各組OD450值/對照組OD450值)×100%。
皮膚含水量係利用多功能皮膚檢測系統MPA 580(C+K electronic,德國)之含水量測定探頭(Corneometer® CM825),藉由導電性變化測量待測區域的皮膚含水量。測試過程中,以Corneometer探頭按壓受試者的皮膚待測區域(避免同一點連續測量),進而得到皮膚含水量數值。由於環境的溫度及濕度會影響皮膚含水量,受試者需要先進入恆溫、恆濕的檢測室平衡20分鐘後才進行測試。測試之環境條件為溫度20℃±1℃,相對溼度50%±10%,且避免空氣擾動。
皮膚光澤度係利用多功能皮膚檢測系統MPA 580(C+K electronic,德國)之光澤度測定探頭(Glossymeter GL 200),藉由照射到皮膚表面光線的直接反射和散射而得到皮膚光澤度數值。
皮膚毛孔數量係利用VISIA-CR全臉膚質檢測儀(Canfield scientific,USA)之全光域波長及偏光波長的光源,於密閉的照相室內拍攝受試者的臉部,取得清晰圖檔後,再以影像軟體分析而得。
數據表示為平均值±標準差(SD)。使用Excel軟體進行統計分析,數據間在統計上的顯著差異以學生t檢驗(student's t-test)判定。
本文所述的鳳梨(Ananas comosus)果皮係指成熟鳳梨果實的表面覆蓋層。鳳梨是一種熱帶水果,其果實是複數鳳梨花的果實結合而成的單一複合果(multiple fruit)。未成熟的鳳梨果實呈綠色,其在成熟後轉為黃色。
為獲得一鳳梨果皮萃取物,自一鳳梨果實取得果皮,並將該鳳梨果皮洗淨及破碎成小塊。其後,以水、醇類、或醇水混合物為溶劑對鳳梨果皮碎塊進行萃取。醇類的例子包括甲醇、乙醇、正丙醇、異丙醇等低碳數的醇類。該溶劑與該鳳梨果皮之重量比為20:1至1:1,較佳為10:1至5:1。萃取溫度為介於50℃至100℃,較佳為75℃至95℃。以下實施例2-6所述鳳梨果皮萃取物皆係依前述方法以水萃取鳳梨果皮0.5至3小時而製得。
經上述萃取步驟所得鳳梨果皮萃取物冷卻至室溫後,可進一步使用200至400目(mesh)之濾網過濾,以移除殘餘固體物。該過濾後的鳳梨果皮萃取物可進一步在45℃至70℃進行減壓濃縮而獲得一濃縮產物。為獲得固態的鳳梨果皮萃取物,可將前述濃縮的鳳梨果皮萃取物以例如冷凍乾燥、噴霧乾燥等乾燥方式去除溶劑,因此獲得乾燥的鳳梨果皮萃取物。
為檢視鳳梨果皮萃取物對細胞內具抗氧化功效之穀胱甘肽(GSH)含量的影響,測定人類皮膚纖維母細胞CCD-966SK或人類肝癌細胞株HepG2以實施例1所述鳳梨果皮萃取物處理後的GSH含量變化。簡言之,將CCD-966SK細胞或HepG2細胞依2×105細胞/孔接種於6孔培養盤,各孔含有2mL MEM細胞培養基。在37℃隔夜培養細胞後,移除該培養基,再以含有0.3125
mg/mL鳳梨果皮萃取物之2mL MEM細胞培養基處理各孔細胞(實驗組)。另設置對照組,係僅以2mL MEM細胞培養基處理CCD-966SK細胞或HepG2細胞。在37℃培養24小時後,收集前述各組細胞以巰基螢光染劑測定GSH含量。
圖1顯示皮膚纖維母細胞經不同處理後的GSH相對含量,其數值表示為相對於對照組的螢光訊號強度的倍數;圖中***表示相比對照組為p<0.001。依據圖1,相比對照組,鳳梨果皮萃取物之處理顯著提升皮膚纖維母細胞的GSH含量至約1.9倍,說明施用鳳梨果皮萃取物能促進皮膚細胞內穀胱甘肽的生成,因此增加皮膚對氧化傷害的抵抗力,例如對紫外線傷害的抵抗力。
圖2顯示HepG2細胞經不同處理後的GSH相對含量;圖中*表示相比對照組為p<0.05。依據該圖,相比對照組,鳳梨果皮萃取物之處理明顯提升HepG2細胞的GSH含量至約1.4倍,說明施用鳳梨果皮萃取物能提高肝細胞內穀胱甘肽的生成。
為檢視鳳梨果皮萃取物對細胞內負責清除有毒物質(如氧化壓力所產生的活性氧物質)之穀胱甘肽S轉移酶(GST)活性的影響,評估人類皮膚纖維母細胞CCD-966SK或外周血單核細胞(PBMC)以實施例1所述鳳梨果皮萃取物處理後,其GST的總體活性變化。簡言之,將CCD-966SK細胞或PBMC細胞依2×105細胞/孔接種於6孔培養盤,各孔含有2mL MEM細胞培養基。在37℃隔夜培養細胞後,移除該培養基,並以含有0.3125mg/mL或0.625mg/mL鳳梨果皮萃取物之2mL MEM細胞培養基處理各孔細胞(實驗組)。另設置對照組,係僅以3mL MEM細胞培養基處理CCD-966SK細胞或PBMC細胞。在37℃培養24小時後,收集前述各組細胞用於GST活性分析。
圖3顯示皮膚纖維母細胞經不同處理後的GST相對活性,其數值表示為相對於對照組的GST活性的倍數;圖中*表示相比對照組為p<0.05。依據圖3,相比對照組,鳳梨果皮萃取物之處理顯著提升皮膚纖維母細胞的GST活性至約1.06倍,說明施用鳳梨果皮萃取物能增加皮膚細胞清除例如活性氧物質(ROS)之自由基的能力,因此有利於減少皮膚的氧化傷害,包括對去氧核醣核酸(DNA)、蛋白質及脂質等細胞組成分子的損傷。
圖4顯示PBMC細胞經不同處理後的GST相對活性;圖中***表示相比對照組為p<0.001。依據該圖,相比對照組,鳳梨果皮萃取物之處理顯著提升PBMC細胞的GST活性至約1.48倍,說明施用鳳梨果皮萃取物能增加體細胞的抗氧化力。
為驗證鳳梨果皮萃取物對皮膚細胞中氧化壓力的調節作用,利用螢光探針DCFH-DA配合流式細胞儀(flow cytometry;Beckman),測定人類皮膚纖維母細胞CCD-966SK以實施例1所述鳳梨果皮萃取物處理後,其在氧化刺激下的活性氧物質含量變化。簡言之,將2×105個CCD-966SK細胞接種於6孔培養盤,各孔含有2mL MEM細胞培養基。在37℃培養細胞24小時後,移除該培養基,並於37℃以2mL含有或不含1mg/mL鳳梨果皮萃取物之MEM細胞培養基處理細胞1小時,再以5μg/mL DCFH-DA溶液處理細胞15分鐘。其後,於37℃以有無過氧化氫的下列方式處理各孔細胞:(a)未經鳳梨果皮萃取物處理的細胞在無過氧化氫刺激下培養1小時(空白對照組);(b)未經鳳梨果皮萃取物處理的細胞以1mM過氧化氫處理1小時(負控制組);或(c)經鳳梨果皮萃取物處理的細胞以1mM過氧化氫處理1小時(實驗組)。其後,各組細胞以PBS溶液清洗二次,於暗處以200μL胰蛋白酶處理5分鐘,再藉由離心(400 xg,10分鐘)收集得各別細胞沉澱物。該細胞沉澱物以PBS溶液清洗一次及再次懸浮,並使用流式細胞儀偵測細胞的螢光強度(二重複試驗)。進行螢光偵測之激發波長為450-490nm,偵測波長為510-550nm。由於DCFH-DA進入細胞後會先被水解為DCFH(二氯二氫螢光素),再被活性氧物質氧化為可發出綠色螢光的DCF(二氯螢光素),經DCFH-DA處理之細胞的螢光強度可反映細胞內活性氧物質含量。
圖5顯示皮膚纖維母細胞經不同處理後的活性氧物質相對含量(%),以負控制組細胞的活性氧物質含量界定為100%;圖中***表示相比負控制組為p<0.001。依據圖5,負控制組相比空白對照組呈現明顯較高的活性氧物質含量,顯示過氧化氫刺激會導致細胞內活性氧物質之累積。然而,相比負控制組,鳳梨果皮萃取物之處理使細胞內活性氧物質降低約45%,顯示鳳梨果皮萃取物本身能清除自由基或提高個體細胞清除自由基的能力。
為檢視鳳梨果皮萃取物對黑色素生成的影響,測定黑色素瘤細胞株B16F10以實施例1所述鳳梨果皮萃取物處理後的黑色素含量變化。簡言之,將B16F10細胞依1.5×105細胞/孔接種於6孔培養盤,各孔含有3mL DMEM細胞培養基。在37℃培養細胞24小時後,移除該培養基,並以含有0.625mg/mL鳳梨果皮萃取物之3mL DMEM細胞培養基處理各孔細胞(實驗組)。另設置一對照組,係僅以3mL DMEM細胞培養基處理細胞。在37℃下培養48小時後,收集前述各組細胞以測定黑色素含量(三重複試驗)。
圖6顯示黑色素瘤細胞經不同處理後的黑色素相對含量,其數值表示為相對於對照組的黑色素含量的百分比;圖中**表示相比對照組為p<0.01。依據該圖,相比對照組,鳳梨果皮萃取物之處理使黑色含量顯著降低約15%,說明鳳梨果皮萃取物具有抑制黑色素生成的效果。
為評估鳳梨果皮萃取物對皮膚含水量、光澤、及毛孔的影響,六位25至40歲之受試者,於檢測前先清潔臉部,並待肌膚平衡穩定後,在左、右半臉各別施用添加一基底精華液之面膜,或添加1%(w/w)實施例1所述鳳梨果皮萃取物及該基底精華液之面膜,其中該基底精華液包含水、馨鮮酮、己二醇、1,3丁二醇、三仙膠、增稠劑、及三乙醇胺。於施用15分鐘後卸下面膜,以按摩方式促進有效成分吸收,再檢測施用前後受試者皮膚的含水量、光澤及毛孔數量。
圖7顯示受試者的平均皮膚含水量變化;圖8顯示受試者的平均皮膚光澤度變化;圖9顯示受試者皮膚的平均毛孔數量變化;圖中百分比各別表示相對於施用前的皮膚含水量、皮膚光澤度及毛孔數量;圖中**表示相比於施用面膜前的數據為p<0.01。依據圖7-9,相比施用前,施用鳳梨果皮萃取物面膜能顯著增加皮膚含水量約20.3%,顯著提升皮膚光澤度約13.1%,及有效減少皮膚毛孔數量約10.3%。該些結果說明該添加鳳梨果皮萃取物之面膜可改善膚質,包括提升皮膚含水量與光澤及減少毛孔。
綜上所述,本發明揭露鳳梨果皮萃取物具有抑制黑色素生成及改善膚質的功效,包括提升皮膚含水量與光澤及減少毛孔。該鳳梨果皮萃取物亦能提升包含皮膚細胞之多種細胞的抗氧化力,藉此減少個體或皮膚的氧化傷害。因此,該鳳梨果皮萃取物可用於製備在皮膚抑制黑色素生成、增加含水量、提升光澤、及減少毛孔之組合物,或製備提升細胞抗氧化力之組合物。該組合物可具有粉末、顆粒、溶液、膠體或膏體之形式,且可製成醫藥品、食品、飲品、或營養補充劑,藉由口服、局部施用於皮膚或其他方式給予一個體。
Claims (7)
- 一種鳳梨萃取物用於製備提升皮膚光澤及減少毛孔之口服地施用或於該皮膚上局部施用的組合物之用途,其中該鳳梨萃取物係以一溶劑萃取一鳳梨果皮而獲得,且該溶劑為水。
- 如申請專利範圍第1項所述之用途,其中該溶劑與該鳳梨果皮之重量比範圍為20:1至1:1。
- 如申請專利範圍第1項所述之用途,其中該萃取係在50℃至100℃進行。
- 一種鳳梨萃取物用於製備提升皮膚細胞抗氧化力之口服地施用或於該皮膚上局部施用的組合物之用途,其中該鳳梨萃取物係以一溶劑萃取一鳳梨果皮而獲得,且該溶劑為水,其中該鳳梨萃取物增加該皮膚細胞內穀胱甘肽的含量至1.9倍,且該鳳梨萃取物的有效量為0.3125mg/mL以上。
- 一種鳳梨萃取物用於製備提升皮膚細胞抗氧化力之口服地施用或於該皮膚上局部施用的組合物之用途,其中該鳳梨萃取物係以一溶劑萃取一鳳梨果皮而獲得,且該溶劑為水,其中該鳳梨萃取物增加該皮膚細胞之穀胱甘肽S轉移酶活性至1.06倍,且該鳳梨萃取物的有效量為0.625mg/mL以上。
- 如申請專利範圍第4或5項所述之用途,其中該溶劑與該鳳梨果皮之重量比範圍為20:1至1:1。
- 如申請專利範圍第4或5項所述之用途,其中該萃取係在50℃至100℃進行。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962886653P | 2019-08-14 | 2019-08-14 | |
US62/886,653 | 2019-08-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202106285A TW202106285A (zh) | 2021-02-16 |
TWI734331B true TWI734331B (zh) | 2021-07-21 |
Family
ID=74568703
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108148714A TWI734331B (zh) | 2019-08-14 | 2019-12-31 | 鳳梨萃取物的護膚用途 |
TW109127839A TW202106321A (zh) | 2019-08-14 | 2020-08-14 | 沙棘萃取物用於改善下呼吸道狀態的組合物的用途 |
TW109127834A TWI749711B (zh) | 2019-08-14 | 2020-08-14 | 凝結芽孢桿菌用於定殖於腸壁以代謝酒精減少酒精吸收之組合物的用途及其食用產品 |
TW109127835A TWI749712B (zh) | 2019-08-14 | 2020-08-14 | 乳酸片球菌tci188及其用於口腔保健的用途 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109127839A TW202106321A (zh) | 2019-08-14 | 2020-08-14 | 沙棘萃取物用於改善下呼吸道狀態的組合物的用途 |
TW109127834A TWI749711B (zh) | 2019-08-14 | 2020-08-14 | 凝結芽孢桿菌用於定殖於腸壁以代謝酒精減少酒精吸收之組合物的用途及其食用產品 |
TW109127835A TWI749712B (zh) | 2019-08-14 | 2020-08-14 | 乳酸片球菌tci188及其用於口腔保健的用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11406673B2 (zh) |
CN (4) | CN112386547B (zh) |
TW (4) | TWI734331B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114107121B (zh) * | 2021-12-06 | 2023-03-21 | 华中农业大学 | 一种凝结芽孢杆菌及其在酒精性肝病的治疗中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201225989A (en) * | 2010-10-29 | 2012-07-01 | Maruzen Pharm Co Ltd | Sugar-free pineapple extract, production method thereof, and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1183839C (zh) * | 2001-09-28 | 2005-01-12 | 陈廷伟 | 含脱氢酶解酒防醉保肝饮料 |
WO2010008879A2 (en) * | 2008-06-24 | 2010-01-21 | Wm. Wrigley Jr. Company | Probiotic chewing gum method of manufacture |
JP2015528705A (ja) * | 2012-08-03 | 2015-10-01 | デュポン ニュートリション バイオサイエンシス エーピーエス | 飼料添加用組成物 |
CN103911326B (zh) * | 2014-03-28 | 2016-08-10 | 内蒙古和美科盛生物技术有限公司 | 凝结芽孢杆菌益生菌制剂的制备 |
CN104017847A (zh) * | 2014-05-05 | 2014-09-03 | 浙江省农业科学院 | 一种芽孢杆菌发酵糖渣原料制备蛋白多肽的方法 |
CN105769702B (zh) * | 2016-04-19 | 2019-06-21 | 广州市暨生元生物科技有限公司 | 一种含菠萝蛋白酶的面膜及其制作方法 |
CN106924141B (zh) * | 2017-03-28 | 2020-06-23 | 海南师范大学 | 一种应用于美白领域的菠萝叶提取物的制备方法 |
CN106667894B (zh) * | 2017-03-28 | 2019-07-19 | 海南师范大学 | 一种菠萝酵素及其作为酪氨酸酶抑制剂的应用 |
CN106955256B (zh) * | 2017-03-28 | 2020-03-06 | 海南师范大学 | 一种菠萝酵素的制备方法及其在美白剂中的应用 |
CN108094792A (zh) * | 2017-12-27 | 2018-06-01 | 天津科技大学 | 一种改善男性亚健康的益生菌发酵功能食品及其制备方法 |
TWI669124B (zh) | 2018-08-09 | 2019-08-21 | 大江生醫股份有限公司 | 芽孢乳酸菌用於製備代謝重金屬及保護肝臟醫藥組成物之用途 |
CN109007676A (zh) * | 2018-08-17 | 2018-12-18 | 江苏新申奥生物科技有限公司 | 一种含乙醛脱氢酶的乳酸菌冻干粉及其制备方法 |
CN111109359B (zh) * | 2019-12-29 | 2022-09-02 | 江南大学 | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 |
-
2019
- 2019-12-31 TW TW108148714A patent/TWI734331B/zh active
- 2019-12-31 CN CN201911411765.3A patent/CN112386547B/zh active Active
-
2020
- 2020-08-14 CN CN202010820580.4A patent/CN112391307B/zh active Active
- 2020-08-14 CN CN202010820586.1A patent/CN112386619A/zh active Pending
- 2020-08-14 TW TW109127839A patent/TW202106321A/zh unknown
- 2020-08-14 CN CN202010820593.1A patent/CN112385846B/zh active Active
- 2020-08-14 TW TW109127834A patent/TWI749711B/zh active
- 2020-08-14 US US16/993,284 patent/US11406673B2/en active Active
- 2020-08-14 TW TW109127835A patent/TWI749712B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201225989A (en) * | 2010-10-29 | 2012-07-01 | Maruzen Pharm Co Ltd | Sugar-free pineapple extract, production method thereof, and application thereof |
Non-Patent Citations (4)
Also Published As
Publication number | Publication date |
---|---|
CN112391307B (zh) | 2022-08-16 |
CN112385846A (zh) | 2021-02-23 |
CN112386547B (zh) | 2022-10-21 |
TWI749712B (zh) | 2021-12-11 |
TW202106868A (zh) | 2021-02-16 |
US11406673B2 (en) | 2022-08-09 |
TW202106285A (zh) | 2021-02-16 |
CN112386619A (zh) | 2021-02-23 |
TW202106321A (zh) | 2021-02-16 |
CN112386547A (zh) | 2021-02-23 |
CN112385846B (zh) | 2024-01-05 |
CN112391307A (zh) | 2021-02-23 |
US20210046126A1 (en) | 2021-02-18 |
TW202106317A (zh) | 2021-02-16 |
TWI749711B (zh) | 2021-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120195923A1 (en) | Use of skin care compositions comprising laminariacea extract for treatment of skin aging signs | |
TWI734474B (zh) | 刺果番荔枝發酵物於製備緊緻肌膚、抗醣化、及基因調節之組合物之用途 | |
CN113384507B (zh) | 一种抗老化组合物及其制备方法和应用 | |
US11213472B2 (en) | VEGFC production promoter | |
TWI754189B (zh) | 普蒂亞花萃取物用於提升皮膚細胞的粒線體活性的用途 | |
TWI734331B (zh) | 鳳梨萃取物的護膚用途 | |
KR101081910B1 (ko) | 키위 추출물을 함유하는 피부톤 개선 및 피부노화방지 효과가 있는 화장료 조성물 | |
TWI809299B (zh) | 紫花地丁萃取物之製備方法 | |
KR101558182B1 (ko) | 흰감국 추출물을 함유하는 피부 외용제 조성물 | |
US20180021248A1 (en) | Cosmetic use of a peppermint extract | |
TWI774046B (zh) | 香瓜茄發酵汁液用於製備提升肌膚抗老能力、提升抗醣化能力、降低黑色素含量、提升肌膚保濕、減少肌膚紋理、減少肌膚皺紋、減少肌膚泛紅及/或減脂組合物的用途 | |
CN112237284A (zh) | 野樱莓汁液用于抑止肌肤老化的用途 | |
Kim et al. | Anti-oxidation and anti-wrinkling effects of Jeju horse leg bone hydrolysates | |
KR20120037179A (ko) | 나노리포좀으로 안정화시킨 감 추출물과 인삼 추출물을 함유하는 항아토피 항노화 화장료 조성물 | |
US20220054398A1 (en) | Use of rubus fruticosus extract for manufacturing a skincare composition | |
EP3130332A1 (en) | Anti-aging external skin preparation | |
TW202106325A (zh) | 重瓣玫瑰萃取物用於製備抑止肌膚老化的組合物之用途 | |
TW202110468A (zh) | 薔薇屬植物萃取物用於抗老化及抗氧化之用途 | |
TWI820448B (zh) | 露莓萃取物用於製備調理肌膚的組合物之用途 | |
TW202038903A (zh) | 複方精油組合物用於調控mmp基因、mc1r基因、krt基因、tert基因、terc基因、及/或ogg1基因表現量的用途 | |
CN112842956B (zh) | 紫花香茅用于调理肌肤的用途 | |
WO2024008187A1 (zh) | 关山樱花萃取物在制备提升皮肤状况或基础代谢率药物中的用途 | |
TWI804771B (zh) | 咖啡櫻桃萃取物用於抵抗及/或減緩膠原蛋白醣化終產物生成之用途 | |
US20220323536A1 (en) | Use of beta-l-aspartyl-l-arginine on senescent skin | |
TW202045134A (zh) | 苦蕎麥種皮萃取物用於減緩肌膚老化的用途及其製備方法 |